145 related articles for article (PubMed ID: 17611408)
21. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
22. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
24. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
[No Abstract] [Full Text] [Related]
25. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
Liu SV; Zneimer S; Tahbaz A; Douer D
Acta Haematol; 2011; 126(2):76-8. PubMed ID: 21502754
[No Abstract] [Full Text] [Related]
27. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
28. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Grosso F; Dileo P; Sanfilippo R; Stacchiotti S; Bertulli R; Piovesan C; Jimeno J; D'Incalci M; Gescher A; Casali PG
Eur J Cancer; 2006 Jul; 42(10):1484-90. PubMed ID: 16737808
[TBL] [Abstract][Full Text] [Related]
29. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
30. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia unlikely related to trabectedin treatment.
Cartoafa M; Kahatt C; Soto-Matos A; Roy E; Lardelli P
Acta Haematol; 2011; 126(4):238-9; author reply 240. PubMed ID: 21952689
[No Abstract] [Full Text] [Related]
32. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
[TBL] [Abstract][Full Text] [Related]
34. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
Theman TA; Hartzell TL; Sinha I; Polson K; Morgan J; Demetri GD; Orgill DP; George S
J Clin Oncol; 2009 Nov; 27(33):e198-200. PubMed ID: 19805684
[No Abstract] [Full Text] [Related]
35. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes.
Grignani G; Le Cesne A; Martín-Broto J
Future Oncol; 2022 Sep; 18(30s):13-22. PubMed ID: 36200954
[TBL] [Abstract][Full Text] [Related]
38. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
[TBL] [Abstract][Full Text] [Related]
39. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
